Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130 Mar 18, 2013 9:00am EDT
Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure Mar 08, 2013 9:00am EST
Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits Jan 23, 2013 9:00am EST
Trevena Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain Nov 14, 2012 9:00am EST
Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting Sep 07, 2012 9:00am EDT
Trevena Angiotensin Receptor Biased Ligand Promotes Cell Survival During Acute Cardiac Injury Sep 04, 2012 1:30pm EDT
Trevena Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered with Furosemide in Dog Heart Failure Model Sep 04, 2012 1:00pm EDT
Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules May 02, 2012 8:30am EDT
Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain Feb 13, 2012 8:30am EST
